These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16420954)

  • 21. A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya.
    Wasunna MK; Rashid JR; Mbui J; Kirigi G; Kinoti D; Lodenyo H; Felton JM; Sabin AJ; Albert MJ; Horton J
    Am J Trop Med Hyg; 2005 Nov; 73(5):871-6. PubMed ID: 16282296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Visceral leishmaniasis (kala-azar) on Ilha de São Luís, Maranhão. Brazil: its evolution and outlook].
    da Silva AR; Viana GM; Varonil C; Pires B; Nascimento Mdo D; Costa JM
    Rev Soc Bras Med Trop; 1997; 30(5):359-68. PubMed ID: 9380895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of rK39 strip test for the diagnosis of visceral leishmaniasis in infants.
    Alborzi A; Rasouli M; Nademi Z; Kadivar MR; Pourabbas B
    East Mediterr Health J; 2006; 12(3-4):294-9. PubMed ID: 17037697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug regimens for visceral leishmaniasis in Mediterranean countries.
    Gradoni L; Soteriadou K; Louzir H; Dakkak A; Toz SO; Jaffe C; Dedet JP; Campino L; Cañavate C; Dujardin JC
    Trop Med Int Health; 2008 Oct; 13(10):1272-6. PubMed ID: 18764817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Visceral Leishmaniasis in children in the Yemen.
    Haidar NA; Diab AB; El-Sheik AM
    Saudi Med J; 2001 Jun; 22(6):516-9. PubMed ID: 11426243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Ecology of leishmaniasis in the south of France. 14. Leishmaniasis of man in the Cévennes: a clinical and biological analysis of visceral and mucosal forms (author's transl)].
    Lanotte G; Rioux JA; Pratlong F
    Ann Parasitol Hum Comp; 1980; 55(6):635-43. PubMed ID: 7469304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute phase proteins and plasma lipoproteins during antimony treatment in infantile visceral leishmaniasis.
    Kallel R; Bekaert ED; Dubois DY; Alcindor LG; Ayrault-Jarrier M; Mebazza A
    Clin Physiol Biochem; 1993; 10(1):8-12. PubMed ID: 8339522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
    Nilforoushzadeh MA; Jaffary F; Ansari N; Siadat AH; Nilforoushan Z; Firouz A
    J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy of thermotherapy to treat cutaneous leishmaniasis in Colombia: a comparative observational study in an operational setting.
    Vega JC; Sanchez BF; Montero LM; Montaña R; Mahecha Mdel P; Dueñes B; Baron AR; Reithinger R
    Trans R Soc Trop Med Hyg; 2009 Jul; 103(7):703-6. PubMed ID: 19059616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Haematological findings in relation to clinical findings of visceral Leishmaniasis in Hazara Division.
    Rai ME; Muhammad Z; Sarwar J; Qureshi AM
    J Ayub Med Coll Abbottabad; 2008; 20(3):40-3. PubMed ID: 19610513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of visceral leishmaniasis in children in the Central-West Region of Brazil.
    Brustoloni YM; Cunha RV; Cônsolo LZ; Oliveira AL; Dorval ME; Oshiro ET
    Infection; 2010 Aug; 38(4):261-7. PubMed ID: 20508967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of renal and hepatic functions in dogs naturally infected by visceral leishmaniasis submitted to treatment with meglumine antimoniate.
    Ikeda-Garcia FA; Lopes RS; Ciarlini PC; Marques FJ; Lima VM; Perri SH; Feitosa MM
    Res Vet Sci; 2007 Aug; 83(1):105-8. PubMed ID: 17150234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nodular lymphangitic subcutaneous dissemination after intralesional antimonial treatment for localized cutaneous leishmaniasis.
    Yébenes M; Cruz I; Cañavate C; Gilaberte M; Baena V; Pujol RM
    Clin Exp Dermatol; 2008 Mar; 33(2):142-4. PubMed ID: 18076691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.
    Mohebali M; Fotouhi A; Hooshmand B; Zarei Z; Akhoundi B; Rahnema A; Razaghian AR; Kabir MJ; Nadim A
    Acta Trop; 2007 Jul; 103(1):33-40. PubMed ID: 17586452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and Epidemiologic Features of Visceral Leishmaniasis in Children in Southwestern China: A Retrospective Analysis From 2001 to 2015.
    Miao R; Wang Z; Guo Q; Wen Y; Liao Q; Zhu Y; Shu M; Wan C
    Pediatr Infect Dis J; 2017 Jan; 36(1):9-12. PubMed ID: 27749663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate.
    Cruz A; Rainey PM; Herwaldt BL; Stagni G; Palacios R; Trujillo R; Saravia NG
    J Infect Dis; 2007 Feb; 195(4):602-8. PubMed ID: 17230422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of cryotherapy versus intralesional meglumine antimoniate (glucantime) for treatment of cutaneous leishmaniasis in children.
    Layegh P; Pezeshkpoor F; Soruri AH; Naviafar P; Moghiman T
    Am J Trop Med Hyg; 2009 Feb; 80(2):172-5. PubMed ID: 19190206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk factors for in-hospital mortality of visceral leishmaniasis patients in eastern Uganda.
    Mueller Y; Mbulamberi DB; Odermatt P; Hoffmann A; Loutan L; Chappuis F
    Trop Med Int Health; 2009 Aug; 14(8):910-7. PubMed ID: 19552645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis.
    Sundar S; Mehta H; Chhabra A; Singh V; Chauhan V; Desjeux P; Rai M
    Clin Infect Dis; 2006 Mar; 42(5):608-13. PubMed ID: 16447104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment.
    Sundar S; Agrawal N; Arora R; Agarwal D; Rai M; Chakravarty J
    Clin Infect Dis; 2009 Sep; 49(6):914-8. PubMed ID: 19663597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.